{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:45:21Z","timestamp":1771843521148,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":195,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1002\/jcph.460","type":"journal-article","created":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T11:04:09Z","timestamp":1420715049000},"page":"620-628","source":"Crossref","is-referenced-by-count":26,"title":["Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis"],"prefix":"10.1002","volume":"55","author":[{"given":"Ping","family":"Chen","sequence":"first","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Melhem","sequence":"additional","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Xiao","sequence":"additional","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mita","family":"Kuchimanchi","sequence":"additional","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jose","family":"Perez Ruixo","sequence":"additional","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,2,18]]},"reference":[{"issue":"2","key":"10.1002\/jcph.460-BIB0001|jcph460-cit-0001","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Therap"},{"issue":"15","key":"10.1002\/jcph.460-BIB0002|jcph460-cit-0002","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"New England J Med"},{"issue":"2","key":"10.1002\/jcph.460-BIB0003|jcph460-cit-0003","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J Pharmacol Exp Therap"},{"issue":"10","key":"10.1002\/jcph.460-BIB0004|jcph460-cit-0004","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/jcph.314","article-title":"A pharmacokinetic\/pharmacodynamic model for AMG 416, a novel calcimimetic peptide, following a single intravenous dose in healthy subjects","volume":"54","author":"Shen","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jcph.460-BIB0005|jcph460-cit-0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ndt\/gft417","article-title":"Velcalcetide (AMG 416), a novel peptide agonist of the calcium sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects","volume":"29","author":"Martin","year":"2014","journal-title":"Nephrol Dialysis Transplant"},{"issue":"1","key":"10.1002\/jcph.460-BIB0006|jcph460-cit-0006","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"Martin","year":"2014","journal-title":"Kid Int"},{"key":"10.1002\/jcph.460-BIB0007|jcph460-cit-0007","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-2873-3","volume-title":"Transformations and Weighting in Regression","author":"Carroll","year":"1988"},{"issue":"4","key":"10.1002\/jcph.460-BIB0008|jcph460-cit-0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10928-009-9127-7","article-title":"Performance in population models for count data, part II: a new SAEM algorithm","volume":"36","author":"Savic","year":"2009","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"10.1002\/jcph.460-BIB0009|jcph460-cit-0009","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01061469","article-title":"Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects","volume":"20","author":"Mandema","year":"1992","journal-title":"J Pharmacokinet Biopharm"},{"issue":"6","key":"10.1002\/jcph.460-BIB0010|jcph460-cit-0010","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jcph.460-BIB0011|jcph460-cit-0011","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1002\/jcph.460-BIB0012|jcph460-cit-0012","first-page":"301","volume-title":"Introduction to Linear Regression Analysis","author":"Douglas","year":"1982"},{"issue":"12","key":"10.1002\/jcph.460-BIB0013|jcph460-cit-0013","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharmaceut Res"},{"issue":"9","key":"10.1002\/jcph.460-BIB0014|jcph460-cit-0014","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","article-title":"Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide","volume":"23","author":"Brendel","year":"2006","journal-title":"Pharmaceut Res"},{"key":"10.1002\/jcph.460-BIB0015|jcph460-cit-0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/9783527609628.ch2","volume-title":"Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development","author":"Tang","year":"2006"},{"issue":"7","key":"10.1002\/jcph.460-BIB0016|jcph460-cit-0016","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/138920009789895499","article-title":"Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies","volume":"10","author":"Lin","year":"2009","journal-title":"Curr Drug Metabol"},{"issue":"4","key":"10.1002\/jcph.460-BIB0017|jcph460-cit-0017","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/03602538409041080","article-title":"Captopril: pharmacology, metabolism and disposition","volume":"15","author":"Migdalof","year":"1984","journal-title":"Drug Metabol Rev"},{"key":"10.1002\/jcph.460-BIB0018|jcph460-cit-0018","first-page":"41","article-title":"The metabolism and pharmacology of D-penicillamine in man","volume":"7","author":"Perrett","year":"1981","journal-title":"J Rheumatol Suppl"},{"issue":"11","key":"10.1002\/jcph.460-BIB0019|jcph460-cit-0019","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1023\/A:1016440707092","article-title":"Oral absorption of D-oligopeptides in rats via the paracellular route","volume":"13","author":"He","year":"1996","journal-title":"Pharmaceut Res"},{"issue":"11","key":"10.1002\/jcph.460-BIB0020|jcph460-cit-0020","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0006-2952(99)00259-2","article-title":"Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide","volume":"58","author":"Hong","year":"1999","journal-title":"Biochem Pharmacol"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.460","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.460\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:04:12Z","timestamp":1657803852000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,18]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.460","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2,18]]}}}